v3.26.1
Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Expenses:        
Research and development $ 3,957,875 $ 939,067 $ 7,849,690 $ 2,443,191
General and administrative 1,561,674 964,676 4,308,236 2,998,127
Loss from operations (5,519,549) (1,903,743) (12,157,926) (5,441,318)
Other income :        
Reimbursement grant income 107,368 183,281 276,021 536,744
Interest income 275 572 961 2,503
Foreign exchange loss 4,295 (29,574) 8,132 (54,294)
Nonoperating Income (Expense) 111,938 154,279 285,114 484,953
Loss before income taxes (5,407,611) (1,749,464) (11,872,812) (4,956,365)
Income tax expense 0 0 800 800
Net loss (5,407,611) (1,749,464) (11,873,612) (4,957,165)
Exchange differences on translation 27,548 164,611 7,230 119,536
Net comprehensive loss $ (5,380,063) $ (1,584,853) $ (11,866,382) $ (4,837,629)
Weighted average number of common shares (in shares) 9,007,474 7,022,678 8,504,968 5,217,343
Loss per common share - basic and diluted (in dollars per share) $ (0.6) $ (0.25) $ (1.4) $ (0.95)